Expression, purification, refolding, and characterization of octreotide-interleukin-2: A chimeric tumor-targeting protein

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 549-556

  Jiang, Jing ^a   Deng, Leixiu ^b   He, Lichun ^b   Liu, Haiting ^b   Wang, Changhai ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b Shandong Simcere Medgenn Biopharmaceutical Co Ltd   (China)

Author keywords

Bioactivity; Expression; Interleukin 2; Octreotide; Purification; Refolding; Somatostatin receptor; Tumor target

Indexed keywords

HYBRID PROTEIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR TARGETED INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; REVERSED PHASE LIQUID CHROMATOGRAPHY; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-2; MASS SPECTROMETRY; MICE; NEOPLASMS; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79960760647     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.723     Document Type: Article

References (31)

1. Arap W, Pasqualini R and Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380, 1998. (Pubitemid 28063372)
2. Nanda PK, Lane SR, Retzloff LB, Pandey US and Smith CJ: Radiolabeled regulatory peptides for imaging and therapy. Curr Opin Endocrinol Diabetes Obes 17: 69-76, 2010.
3. Bussolati B, Grange C, Tei L, et al: Targeting of human renal tumor-derived endothelial cells with peptides obtained by phage display. J Mol Med 85: 897-906, 2007. (Pubitemid 47077113)
4. Carter PJ: Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357, 2006.
5. Curnis F, Sacchi A, Borgna L, et al: Enhancement of tumor necrosis factor alpha Anti-tumor immunotherapeutic properties by targeted delivery aminopeptidase N(CD13). Nat Biotechnol 18: 1185-1190, 2000.
6. Schliemann C, Palumbo A, Zuberbuhler K, et al: Complete eradicationof human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113: 2275-2283, 2009.
7. Halin C, Rondini S, Nilsson F, et al: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20: 264-269, 2002. (Pubitemid 34205419)
8. Ebbinghaus C, Ronca R, Kaspar M, et al: Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116: 304-313, 2005. (Pubitemid 40967270)
9. Halin C, Gafner V, Villani ME, et al: Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63: 3202-3210, 2003. (Pubitemid 36735873)
10. Melder RJ, Osborn BL, Riccobene T, et al: Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 54: 535-547, 2005.
11. Lotze MT, Matory YL, Ettinghausen SE, et al: In vivo administrationof purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 2865-2875, 1985. (Pubitemid 16217166)
12. Smith KA: IL-2. In: Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. Oppenheim JJ and Feldman M (eds). Academic Press, New York, 2000.
13. Yang JC, Topalian SL, Schwartzentruber DJ, et al: The use of polyethyleneglycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 76: 687-694, 1995.
14. Marlind J, Kaspar M, Trachsel E, et al: Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14: 6515-6524, 2008.
15. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D and Bruns C: Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2: 999-1017, 2003. (Pubitemid 37540581)
16. Kerros C, Cavey T, Sola B, Jauzac P and Allouche S: Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. J Exp Clin Cancer Res 28: 77, 2009.
17. Schindler M, Holloway S, Humphrey PP, et al: Localization of the somatostatin sst2(a) receptor in human cerebral cortex, hippocampusand cerebellum. Neuroreport 9: 521-525, 1998. (Pubitemid 28109216)
18. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S and Sasano H: Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52: 605-611, 2005. (Pubitemid 41609051)
19. Strowski MZ and Blake AD: Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol 286: 169-179, 2008.
20. Reubi JC and Laissue JA: Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16: 110-115, 1995.
21. Reubi JC, Waser B, Schaer JC and Laissue JA: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28: 836-846, 2001. (Pubitemid 32662546)
22. Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B and Janson ET: Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 20: 59-67, 2003. (Pubitemid 36344027)
23. de Herder WW, Hofland LJ, van der Lely AJ and Lamberts SW: Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10: 451-458, 2003. (Pubitemid 38094881)
24. Kumar U, Grigorakis SI, Watt HL, et al: Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 92: 175-186, 2005. (Pubitemid 40933583)
25. Scarpignato C and Pelosini I: Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 47 (Suppl 2): S1-S29, 2001.
26. Sun LC and Coy DH: Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 8: 2-10, 2011.
27. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H and Susini C: Antitumor effects of somatostatin. Mol Cell Endocrinol 286: 230-237, 2008.
28. Sambrook J, Fritsch EF and Maniatis T (eds): Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory Press, New York, 1989.
29. Weston L: Measurement of interleukin-2 by bioassay. In: Interleukin Protocols. O'Neill LAJ and Bowie A (eds). Humana Press Inc., Totowa, pp186-192, 2001.
30. Yaciuk P: Co-immunoprecipitation of protein complexes. In: Adenovirus Methods and Protocols: Ad Proteins, RNA Lifecycle, Host Interactions, and Phylogenetics. Wold WS and Tollefson AE (eds). Vol 2, Human Press Inc., Totowa, pp103-111, 2007.
31. Anfinsen CB and Haber E: Studies on the reduction and re-formation of protein disulfide bonds. J Biol Chem 236: 1361-1363, 1961.